BioSensics
This is an observational study. Subjects with a documented diagnosis of spinocerebellar ataxia (SCA) will be screened and recruited to participate at two clinical sites: Johns Hopkins University (JHU) and Columbia University (CU). Researchers at BioSensics, JHU, and CU will use wearable sensors computerized speech, psychomotor, and ocular assessments to evaluate the feasibility of using digital health technologies to monitor symptoms in SCA. Researchers will also measure the Scale for the Assessment and Rating of Ataxia (SARA) and other SCA clinical assessments. The solution will be deployed for 25 participants with SCA for approximately 12 months with 5 study visits (Screening/Baseline, Day 1, Day 30, Day 90, Day 180, Day 360).
The spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of rare, autosomal dominant neurodegenerative disorders characterized by progressive degeneration of the cerebellum and its connecting pathways. The four most common subtypes (SCA1, SCA2, SCA3, and SCA6) are caused by expanded polyglutamine-coding CAG repeats, and collectively account for the majority of dominantly inherited ataxias worldwide. The cardinal feature across subtypes is progressive ataxia affecting gait, stance, limb coordination, and speech, frequently accompanied by oculomotor abnormalities a…
Inclusion Criteria: * Male or female, aged 18-75 years * Fluent in English (able to speak and read) * Able to ambulate at least 10 meters independently or with a cane, without other assistive devices, as determined by the investigator * Able to independently perform all study activities safely, as determined by the investigator * Willing and able to provide informed consent and comply with all study procedures * Genetically or clinically confirmed diagnosis of spinocerebellar ataxia (SCA 1, 2, 3, or 6) Exclusion Criteria: * Individuals who are unable to ambulate at least 10 meters independe…
Arctuva estimate
Verify or correct the compensation shown for this listing.